This press release was posted on Pfizer’s website<\/a> on December 4, 2023.<\/p>\n

A dual JAK3\/TEC inhibitor, LITFULO\u2122 (ritlecitinib) is approved for adults and adolescents over 12 years of age for treatment of severe alopecia areata.<\/em><\/p>\n

KIRKLAND, QC, December 4, 2023 \u2013 Today, Pfizer Canada announced that Health Canada has granted a Notice of Compliance (NOC) for LITFULO\u2122 (ritlecitinib). A once-daily oral treatment, LITFULO is the first and only treatment approved by Health Canada for individuals 12 years of age and older with severe alopecia areata.[i] Approximately two per cent of the global population are affected by alopecia areata which is an autoimmune disease where the immune system attacks the body\u2019s hair follicles causing patchy to complete hair loss on the scalp, face and\/or body. [ii],[iii],[iv]<\/p>\n

\u201cFor patients with substantial hair loss, alopecia areata can be difficult to manage physically and emotionally, especially for younger people,\u201d said Dr. Melinda Gooderham, dermatologist at the SKiN Centre for Dermatology in Peterborough, Ontario. \u201cAs a physician, it has been frustrating to have so little to offer patients. I\u2019m pleased to have a new option available.\u201d<\/p>\n

An estimated 775,000 Canadians are affected by alopecia areata at some point in their lifetime, with most people starting to show signs in their teens through to their 30s. However, patients can start to develop symptoms at any age with nearly 20 per cent of people being diagnosed before the age of 18.[v],[vi],[vii]<\/p>\n

“Alopecia areata has a devastating impact on a person\u2019s mental health and quality of life,\u201d said\u00a0Carolynne Harrison, President of the\u00a0Canadian\u00a0Alopecia\u00a0Areata\u00a0Foundation (CANAAF). \u201cUntil now, there have been no approved medical treatment options to help patients and their families living with this condition. The alopecia community across Canada is looking forward to access to a new\u00a0treatment option for both adolescents and adults with the severe form of alopecia areata.\u201d<\/p>\n

About Alopecia Areata<\/strong>
\nAlopecia areata is a T cell-mediated autoimmune disease affecting the hair follicles. Inflammation in the hair follicles causes hair loss and the loss of the ability to regrow hair until the response is suppressed.[viii] This hair loss often occurs on the scalp, but it can also affect eyebrows, eyelashes, facial hair, and other areas of the body.[ix],[x] Alopecia areata can affect people of any age, gender, race, or ethnicity and can cause considerable burden beyond hair loss.[xi],[xii],[xiii],[xiv]<\/p>\n

\u201cThe approval of LITFULO marks an important milestone for Canadians, including those as young as 12, living with severe hair loss from alopecia areata,\u201d said Fr\u00e9d\u00e9ric Lavoie, Inflammation and Immunology Lead for Pfizer Canada. \u201cThis approval represents the first treatment option approved by Health Canada for severe alopecia areata. As a leader in inflammation and immunology, we at Pfizer Canada are immensely proud to be bringing this new option for Canadians living with this challenging autoimmune disease.\u201d<\/p>\n

Pfizer Canada is currently assessing the timeline for the availability of LITFULO in Canada and is committed to bringing supply of this medicine to Canadians as quickly as possible.<\/p>\n

About LITFULO\u2122<\/strong>
\nLITFULO is used to treat severe alopecia areata in people 12 years of age and older.[xv] LITFULO is an inhibitor of JAK3 and the TEC family kinases.[xvi] Inhibition of JAK3 and TEC kinase family members by LITFULO may block signaling of cytokines and cytolytic activity of T cells, which is implicated in the pathogenesis of alopecia areata.[xvii]<\/p>\n

About Pfizer Canada<\/strong>
\nPfizer Canada ULC is the Canadian operation of Pfizer Inc., one of the world’s leading biopharmaceutical companies. Our diversified health care portfolio includes some of the world’s best known and most prescribed medicines and vaccines. We apply science and our global resources to improve the health and well-being of Canadians at every stage of life. Our commitment is reflected in everything we do, from our disease awareness initiatives to our community partnerships. To learn more about Pfizer Canada, visit\u00a0pfizer.ca<\/a>\u00a0or you can follow us on\u00a0LinkedIn<\/a>,\u00a0Facebook<\/a>,\u00a0X<\/a>\u00a0or\u00a0YouTube<\/a>.<\/p>\n

For more information:<\/strong>
\nCorporate Affairs Canada
\n1-866-9Pfizer (1 866 973-4937)
\ncorporate.affairs.canada@pfizer.com<\/p>\n

[i] LITFULO Product Monograph. Available at\u00a0www.pfizer.ca. November 29, 2023.<\/p>\n

[ii] Canadian Alopecia Areata Foundation. What is Alopecia Areata? Accessed November 2023 at https:\/\/www.canaaf.org\/about-alopecia-areata\/.<\/p>\n

[iii] Canadian Dermatology Association. Alopecia. Accessed November 2023 at https:\/\/dermatology.ca\/public-patients\/hair\/alopecia\/<\/p>\n

[iv] Islam N, Leung PSC, Huntley AC, et al. The autoimmune basis of alopecia areata: a comprehensive review. Autoimmun Rev. 2015:14(2):81-89.<\/p>\n

[v] National Institute of Arthritis and Musculoskeletal and Skin Diseases. Alopecia Areata. Accessed November 2023 at https:\/\/www.niams.nih.gov\/health-topics\/alopecia-areata<\/p>\n

[vi] Caldwell CC, Saikaly SK, Dellavalle RP, et al. Prevalence of pediatric alopecia areata among 572,617 dermatology patients. J Am Acad of Dermatol. 2017;77(5):980-981.<\/p>\n

[vii] Gilding AJ, Ho N, Pope E, Sibbald C. The Burden of Disease in Alopecia Areata: Canadian Online Survey of Patients and Caregivers. JMIR Dermatol. 2022 Oct 6;5(4):e39167<\/p>\n

[viii] Canadian Alopecia Areata Foundation. What is Alopecia Areata? Accessed November 2023 at https:\/\/www.canaaf.org\/about-alopecia-areata\/.<\/p>\n

[ix] Canadian Dermatology Association. Alopecia. Accessed November 13, 2023 at https:\/\/dermatology.ca\/public-patients\/hair\/alopecia\/<\/p>\n

[x] Islam N, Leung PSC, Huntley AC, et al. The autoimmune basis of alopecia areata: a comprehensive review. Autoimmun Rev. 2015:14(2):81-89.<\/p>\n

[xi] Canadian Dermatology Association. Alopecia. Accessed November 13, 2023 at https:\/\/dermatology.ca\/public-patients\/hair\/alopecia\/<\/p>\n

[xii] Islam N, Leung PSC, Huntley AC, et al. The autoimmune basis of alopecia areata: a comprehensive review. Autoimmun Rev. 2015:14(2):81-89.<\/p>\n

[xiii] Food and Drug Administration. The voice of the patient: a series of reports from the U.S. Food and Drug Administration\u2019s (FDA\u2019s) patient-focused drug development initiative. Silver Spring, MD:FDA;2018. Available from:\u00a0https:\/\/www.fda.gov\/files\/about%20fda\/published\/Alopecia-Areata–The-Voice-of-the-Patient.pdf. Accessed November 11, 2023.<\/p>\n

[xiv] Stefanaki C, Kontochristopoulos G, Hatzidimitrakib E, et al. A Retrospective Study on Alopecia Areata in Children: Clinical Characteristics and Treatment Choices. Skin Appen Dis. 2021.<\/p>\n

[xv] LITFULO Product Monograph. Available at\u00a0www.pfizer.ca. November 29, 2023.<\/p>\n

[xvi] Ibid.<\/p>\n

[xvii] Ibid.<\/p>\n","protected":false},"excerpt":{"rendered":"

This press release was posted on Pfizer’s website on December 4, 2023. A dual JAK3\/TEC inhibitor, LITFULO\u2122 (ritlecitinib) is approved for adults […]<\/p>\n","protected":false},"author":3,"featured_media":11673,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[4],"tags":[],"class_list":["post-17727","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-research"],"yoast_head":"\n